Teva Pharmaceutical Industries LimitedNYSE: TEVA

Teva Pharmaceuticals sued rival drugmaker Corcept Therapeutics in federal court in San Francisco on Thursday, accusing it of monopolizing the market for mifepristone-based Korlym, used to treat a rare hormonal disorder called Cushing's syndrome.

TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.

Assess Teva Pharmaceutical Industries (TEVA) anticipated performance for the quarter ending March 2024 by delving deeper into key metrics rather than solely relying on traditional Wall Street projections.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has confirmed that Richard Francis, Teva's President and CEO, will be speaking at the 2024 Bank of America Healthcare Conference on May 14, 2024. The presentation will start at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time). To watch the live webcast, please go to Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. The webcast will also be available for viewing later on.

Teva Pharmaceutical Industries Ltd. NYSE: TEVA is a global pharmaceutical company in the medical sector specializing in generic and specialty medications.

Teva Pharmaceutical Industries will remain a single company for both generic and branded drugs since generics help to fund research and development of its innovative medicines, Chief Executive Richard Francis said on Tuesday.

Shares of Teva Pharmaceuticals (TEVA) are trending up as the company reported its fourth-quarter earnings, beating Wall Street expectations on both its top and bottom line. On Wednesday, the company confirmed it will sell its active pharmaceutical ingredients business as part of CEO Richard Francis' “pivot to growth” strategy.

Although the revenue and EPS for Teva Pharmaceutical Industries Ltd. (TEVA) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Teva Pharmaceutical Industries will divest its active pharmaceutical ingredient (API) unit to focus on its core business, the world's largest generic drugs maker said on Wednesday.